GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

GSK Plc (NYSE:GSK) stock fell 5% after a U.S. Food and Drug Administration advisory panel voted against recommending approval for its blood cancer drug Blenrep, citing concerns that risks outweigh ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for a prefilled syringe presentation of ...

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

(Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the prevention of shingles.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

GSK plc (NYSE:GSK) reported solid financial results for fiscal Q4 2024, reflecting strong growth across key metrics. Its sales grew 8% to over £31 billion in 2024, and core operating profit rose ...

GSK said it now expects adjusted operating profit to increase between 13-15% for the year after it reported a rise in net profit in the third quarter, mainly due to the U.S. launch of its Arexvy ...

The U.S. FDA has approved a prefilled syringe presentation of GSK plc’s SHINGRIX for the prevention of shingles.